A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis

Parthasaradhi, Anchala; Singh, Vinay Kumar; Parasramani, SG; Yadav, Nishi; Krupashankar, DS; Soni, Monika; Bansal, Rakesh Kumar

doi:10.4103/idoj.idoj_330_16

Cited by 7 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety of itolizumab was also established in a case series of five patients reported by Nott et al,13 a case series of seven patients by Singh,14 a case series of 20 patients by Parthasaradhi,15 a case series of 155 patients by Parthasaradhi et al,16 a case series of five patients by Pai and Pai,17 a case report presented by Trasi et al,18 a case report by Gupta et al,19 and a case report by Budamakuntla et al20 In all the clinical studies and individual case reports or case series, itolizumab was safe and well tolerated (Tables 2 and 3).…”

Section: Safety and Efficacy Of Itolizumab For Psoriasis In Indian Pamentioning

confidence: 89%

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

Budamakuntla

Shree-Lakshmi

Bansal

et al. 2019

PTT

View full text Add to dashboard Cite

Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords “anti-CD6”, “psoriasis”, “phase trials”, “case series”, and “case reports”. The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis.

show abstract

Section: Safety and Efficacy Of Itolizumab For Psoriasis In Indian Pamentioning

confidence: 89%

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

Budamakuntla

Shree-Lakshmi

Bansal

et al. 2019

PTT

View full text Add to dashboard Cite

show abstract

“…The DLQI score ranges between 0 and 30, with higher scores indicating a greater effect of the disease on quality of life. [25][26]…”

Section: Scales and Questionnairesmentioning

confidence: 99%

Evaluation of Depression and Quality of Life in Patients With Psoriasis

Sriramoju¹,

Dunde²,

Eggadi³

et al. 2022

Int J Dermatol Venereol

View full text Add to dashboard Cite

Objective: To measure the prevalence of depression in patients with psoriasis and to evaluate the relationship between the severity of psoriasis and depression and its effect on patients' quality of life. Methods: A total of 154 patients with a confirmed diagnosis of psoriasis were assessed to determine the severity of psoriasis based on the psoriasis area and severity index score, presence, and severity of depression using the patient health questionnaire 9, and quality of life using the dermatology life quality index 10. Pearson correlation coefficient was used to demonstrate the relationship between continuous variables with 95% confidence intervals (CIs); P < 0.00001 was taken to indicate statistical significance. Results: The severity of psoriasis was mild in 36.36% of patients, moderate in 25.97%, severe in 32.47%, and very severe in 5.20%. Of the 154 patients, 139 (90.3%) had depression; the severity of depression was mild in most affected patients (46.7%) and severe in 2.6% of patients. Psoriasis had a moderate effect on the quality of life in 37.01% of patients and a very large effect in 33.77% of patients. The severity of psoriasis was positively correlated with depression (Pearson correlation coefficient, r = 0.42, P<0.00001, 95% CI: 0.28-0.54) and quality of life (r = 0.43, P<0.00001, 95% CI: 0.29-0.55). Conclusion: Depression is a common comorbidity in patients with psoriasis. The severity of psoriasis is positively correlated with the severity of depression and is associated with poor quality of life.

show abstract

“…18-82 years old), and even focused on elderly psoriatic subjects (>65 years old) [15][16][17][18]. Some of the papers revealed almost equal proportions between male and female study subjects although at times the percentage of females was higher than the percentage of males [19][20][21][22][23]. As for the race of the evaluated patients, most of the studies demonstrated differentiation in the patients' race.…”

Section: Plos Onementioning

confidence: 99%

The effects of selected biologics and a small molecule on Health-Related Quality of Life in adult plaque psoriasis patients: A systematic review and meta-analysis

2020

View full text Add to dashboard Cite

Background The Dermatology Life Quality Index (DLQI) is commonly used to assess the quality of life of patients with skin diseases. Clinical trials confirm the positive effect of the use of biologics and new molecules on the quality of life of patients with plaque psoriasis. Main objectives Investigation of the effect of infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib on Health-Related Quality of Life (HRQOL) measured by the DLQI in adult plaque psoriatic patients with respect to the patients’ race, type of used agent/placebo, agent’s dosage and treatment duration as well as the DLQI score prior to and after commencement of treatment. Material and methods Systematic literature searching for referential papers written in English using four databases: PubMed, EMBASE, Scopus, ClinicalTrials.gov as well as and manual searching (Google) Cochran’s (Q) and I2 tests were used for evaluation of heterogeneity or the degree of variation in the true effect size estimates between the analysed studies. The standardized mean difference (the SMD; Hedge’s g score) was applied to measure the differences between the two means (i.e. two groups: treated vs non-treated or treated vs placebo). The data coding and Hedge's g values were calculated according to the guidance of MetaXL software version 5.3. Main results 43 studies, in total 25,898 individuals, were evaluated by the DLQI and weighted mean scores were derived for the analysis. The mean DLQI scores ranged from 6.83 to 17.8 with the overall DLQI score of 12.12 (95%CI: 11.24 to 13.06). A random-effects model demonstrated significant considerable heterogeneity of the study results (I2 = 98%; p<0.001). Conclusion Infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib in adult plaque psoriatic patients improved HRQOL measured by the DLQI. The patients with lower quality of life before treatment obtained better results.

show abstract

A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis

Cited by 7 publications

References 9 publications

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

Evaluation of Depression and Quality of Life in Patients With Psoriasis

The effects of selected biologics and a small molecule on Health-Related Quality of Life in adult plaque psoriasis patients: A systematic review and meta-analysis

Contact Info

Product

Resources

About